RTP Mobile Logo

Regional Meetings 2018

Visiting Professors: Investigator Perspectives on the Management of Soft Tissue Sarcoma — An Interactive Grand Rounds Series

Research To Practice (RTP) is pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of soft tissue sarcoma. Each session in this regional series will feature a blend of didactic presentation, interactive polling of attendees using keypad devices and follow-up audience Q&A.

If you are interested in hosting a session at your institution, please contact our Meeting Services Department at Meetings@ResearchToPractice.com or call (800) 233-6153.

Learn about our other CME series Investigator Perspectives on Current Clinical Issues and Ongoing Research Shaping the Management of Follicular Lymphoma and Novel and Emerging Therapeutic Strategies in the Management of Non-Small Cell Lung Cancer.

Event Details

Schedule of Events:

Meetings to be announced

There is no registration fee for these events. However, preregistration is advised as seating is limited.

Agenda

Each 1-hour session will include 3 topic modules focused on the current management of soft tissue sarcoma (STS) and will endeavor to review available emerging research data and provide perspectives on the optimal integration of novel agents and strategies into established treatment algorithms. Each event will employ an identical format that will include the following elements:

  • Discussion of Steering Committee Members’ Treatment Recommendations
  • Review of Available Clinical Research Findings
  • Integration of Interactive Audience Polling Results
MODULE 1 Diagnosis and Classification of STS; Management of Locoregional Disease MODULE 2 Current First-Line Management of Metastatic STS MODULE 3 Protocol and Nonresearch Options for Patients with Relapsed/Refractory STS; Future Directions and Promising Approaches

Each session will conclude with a 5-minute Q&A segment

STEERING COMMITTEE MEMBERS

Mark Agulnik, MD
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Kristen Ganjoo, MD
Associate Professor of Medicine
Director, Stanford Sarcoma Program
Stanford Cancer Institute
Stanford, California

Suzanne George, MD
Clinical Director
Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Shreyaskumar Patel, MD
Robert R Herring Distinguished Professor of Medicine
Center Medical Director, Sarcoma Center
The University of Texas MD Anderson Cancer Center
Houston, Texas
Seth M Pollack, MD
Assistant Member
Fred Hutchinson Cancer Research Center
Clinical Research Division
Assistant Professor
University of Washington
Division of Oncology
Seattle, Washington

Richard F Riedel, MD
Associate Professor, Division of Medical Oncology
Associate Director, Duke Sarcoma Program
Member, Duke Cancer Institute
Duke University Health System
Durham, North Carolina

Brian A Van Tine, MD, PhD
Medical Oncology
Associate Professor of Medicine
Sarcoma Program Director
Barnes-Jewish Hospital
Washington University in St Louis
St Louis, Missouri

Victor M Villalobos, MD, PhD
Assistant Professor of Medicine
Director, Sarcoma Medical Oncology
Director, Molecular Oncology Therapeutics Team
University of Colorado Denver
Denver, Colorado
 

CE Information

Target Audience:
This activity is intended for general medical oncologists and their support staff who treat a variety of solid tumors and hematologic cancers, including soft tissue sarcoma (STS), rather than clinicians with a specialized interest in this unique and challenging disease.

Learning Objectives:

  • Assess the importance of multidisciplinary collaboration in the diagnosis and management of STS, and use this information to guide therapeutic decision-making or tertiary care referrals.
  • Recognize the histologic diversity of adult STS and appreciate how inaccurate diagnoses can compromise treatment planning and long-term outcomes for patients with the various forms of this disease.
  • Evaluate available clinical trial evidence to discern the role of neoadjuvant and adjuvant chemotherapy in the clinical management of STS.
  • Consider histology, anatomic location, extent of disease, performance status and other clinical and biologic factors to guide the selection of first- and later-line therapy for patients with various forms of STS.
  • Appreciate the pathophysiology of STS development, proliferation and growth, and recognize the biologic rationale for therapeutically targeting the platelet-derived growth factor receptor pathway.
  • Develop an understanding of the mechanism of action, available efficacy and safety data and FDA-approved indication for olaratumab in patients with unresectable or metastatic STS, and use this knowledge to appropriately integrate this novel approach into current clinical algorithms.
  • Recognize the toxicities and adverse events associated with novel agents employed in the management of STS, and formulate strategies to minimize and manage these side effects.
  • Recall new data with investigational agents and strategies demonstrating promising activity in STS, and discuss ongoing trial opportunities with eligible patients.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Commercial Support:
These activities are supported by an educational grant from Lilly.